Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$64.12 - $128.71 $43,473 - $87,265
-678 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $48,327 - $81,868
678 New
678 $54,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.